Bylaws
OPTN Bylaws
OPTN Bylaws outline membership requirements to participate in the U.S. transplant network. The Membership & Professional Standards Committee (MPSC) oversees the bylaws.
OPTN Bylaws
Updated 7/25/2024Evaluation plan
The OPTN evaluation plan provides guidance to member transplant centers, OPOs and histocompatibility labs on how to comply with OPTN policies and bylaws.
Evaluation Plan Updated 9/3/2024Recent updates
The OPTN Bylaws were last updated on 7/25/2024 with changes related to Enhance Transplant Program Performance Monitoring System, Phase 3.
| Update | Section | Effective date |
|---|---|---|
| Enhance Transplant Program Performance Monitoring System, Phase 3 |
Appendix D: Membership Requirements for Transplant Hospitals and Transplant Programs |
7/25/2024 |
| Establish Code of Conduct and Whistleblower Protections |
2.7: OPTN Code of Conduct 2.9 Public Statements by Directors 2.10 Whistleblower Protection 7.8 OPTN Code of Conduct 7.9 Public Statements by Committee Members and OPTN Volunteers 9.5 Review Boards |
7/1/2024 |
| Proposal to Address the Relationship of the OPTN and OPTN Contractor Board |
2.8: Relationship of the OPTN Board and the OPTN Contractor |
3/30/2024 |
| Establish Membership Requirements for Uterus Transplant Programs |
Appendix J: Membership Requirements for Vascularized
|
12/5/2023 |
| Apply Transplant Notification Requirements for VCA Program Inactivation (PDF) |
Appendix J: Membership and Personnel Requirements for Appendix K: Transplant Program Inactivity, Withdrawal, |
09/14/2023 |
Enhance Transplant Program Performance Monitoring System, Phase 2 (July 2023) (PDF)
|
Appendix D, D.12.A: Transplant Program Performance except adult and pediatric criteria for pre-transplant mortality rate ratio |
07/27/2023 |
|
OPTN Bylaws Corrections 2022 |
Appendix C.3.A: Histocompatibility Laboratory Director Qualifications Appendix M: Definitions |
12/5/2022 |
|
Enhance Transplant Program Performance Monitoring System, Phase 1 (July 2022) (PDF)
|
Appendix D, D.12.A.: Transplant Program Performance except adult and pediatric criteria for pre-transplant mortality rate ratio and offer acceptance rate ratio Appendix L, L.3: Medical Peer Review Appendix L, L.6: Peer Visits Appendix L, L.9: Informal Discussions Appendix L, L.15: Costs and Expenses Appendix M: Definitions |
07/14/2022 |
| Correction to Primary Pediatric Liver Transplant Program Requirements (PDF) |
F.4.E.4: Combined Pediatric Gastroenterology/Transplant Hepatology Training and Experience Pathway F.7.C.2.d: Conditional Approval for a Pediatric Component |
6/27/2022 |
| Administrative Changes |
1.1.E: Member Compliance 3.1: Composition |
12/6/2021 |
| Clarification of Policies and Bylaws Specific to Vascularized Composite Allografts (PDF) |
Appendix J: Membership Requirements for Vascularized Composite Allograft (VCA) Transplant Programs Appendix M: Definitions |
06/14/2021 |
| List Covered Body Parts for VCA |
D: Membership Requirements for Transplant Hospitals and Transplant Programs D.3: Designated Transplant Program Requirement J: Membership Requirements for Vascularized Composite Allograft (VCA) Transplant Programs J.3: Primary VCA Transplant Surgeon Requirements M: Definitions |
06/14/2021 |
| Align VCA Program Membership Requirements with Other Programs |
D.7: Transplant Program Key Personnel J: Membership and Personnel Requirements for Vascularized Composite Allograft (VCA) Transplant Programs J.1: Program Director, Primary Transplant Physician, and Primary Transplant Surgeon J.2: Primary VCA Transplant Physician Requirements J.3 Primary VCA Transplant Surgeon Requirements |
06/14/2021 |
| Membership Requirements for VCA Transplant Programs |
J: Membership and Personnel Requirements for Vascularized Composite Allograft (VCA) Transplant Programs J.1: Program Director, Primary Transplant Physician, and Primary Transplant Surgeon J.2: Primary VCA Transplant Physician Requirements J.3 Primary VCA Transplant Surgeon Requirements |
06/14/2021 |
If you have questions about these updates, please contact MembershipRequests@unos.org.